Tapio Hellman1,2, Tuomas Kiviniemi1, Ilpo Nuotio2, Fausto Biancari1,3,4, Tuija Vasankari1, Juha Hartikainen5, Mika Lehto6, K E Airaksinen1. 1. Heart Center, Turku University Hospital and University of Turku, Turku, Finland. 2. Department of Medicine, Turku University Hospital and University of Turku, Turku, Finland. 3. Department of Surgery, Turku University Hospital and University of Turku, Turku, Finland. 4. Department of Surgery, Oulu University Hospital and University of Oulu, Oulu, Finland. 5. Heart Center, Kuopio University Hospital and University of Eastern Finland, Kuopio, Finland. 6. Heart and Lung Center, Helsinki University Hospital and University of Helsinki, Finland.
Abstract
BACKGROUND: Electrical cardioversion (CV) is essential in rhythm management of atrial fibrillation (AF). However, optimal timing of CV remains unknown. HYPOTHESIS: Timing of CV in AF is associated with risk of adverse events. METHODS: We analyzed the effect of AF episode duration on safety and efficacy of electrical CV in a multicenter, multicohort study exploring 4356 CVs in 2530 patients on oral anticoagulation. The composite adverse outcome included unsuccessful CV, acute arrhythmic complications, thromboembolic events, mortality, and AF recurrence within 30-day follow-up. RESULTS: Study groups were stratified according to duration of index AF episode (<24 h, 24-48 h, 48 h-30d, and > 30d), consisting of 1767, 516, 632, and 1441 CVs, respectively. CVs were unsuccessful in 8.5% (<24 h), 5.4% (24-48 h), 11.1% (48 h-30d), and 13.9% (>30d), respectively (P < 0.01). Occurrence of thromboembolic events (0.1%), mortality (0.1%), and asystole >5 seconds (0.7%) within 30-day follow-up was infrequent and comparable in the study groups. AF recurrence within 30 days after initially successful CVs was 29.8% (<24 h), 26.5% (24-48 h), 37.3% (48 h-30d), and 30.3% (>30d), respectively (P < 0.01). Composite adverse outcome occurred in 1669 (38.4%) CVs, and index AF episode >48 hours was an independent predictor for the composite endpoint (OR: 1.49, 95% CI: 1.28-1.74, P < 0.01) in multivariate analysis. CONCLUSIONS: Optimal timing of CV for AF showed a J-shaped curve, with fewest adverse outcomes in patients with CV performed 24 to 48 hours after onset of AF. In patients with rhythm-control strategy, delaying CV >48 hours is associated with increased risk for adverse outcomes.
BACKGROUND: Electrical cardioversion (CV) is essential in rhythm management of atrial fibrillation (AF). However, optimal timing of CV remains unknown. HYPOTHESIS: Timing of CV in AF is associated with risk of adverse events. METHODS: We analyzed the effect of AF episode duration on safety and efficacy of electrical CV in a multicenter, multicohort study exploring 4356 CVs in 2530 patients on oral anticoagulation. The composite adverse outcome included unsuccessful CV, acute arrhythmic complications, thromboembolic events, mortality, and AF recurrence within 30-day follow-up. RESULTS: Study groups were stratified according to duration of index AF episode (<24 h, 24-48 h, 48 h-30d, and > 30d), consisting of 1767, 516, 632, and 1441 CVs, respectively. CVs were unsuccessful in 8.5% (<24 h), 5.4% (24-48 h), 11.1% (48 h-30d), and 13.9% (>30d), respectively (P < 0.01). Occurrence of thromboembolic events (0.1%), mortality (0.1%), and asystole >5 seconds (0.7%) within 30-day follow-up was infrequent and comparable in the study groups. AF recurrence within 30 days after initially successful CVs was 29.8% (<24 h), 26.5% (24-48 h), 37.3% (48 h-30d), and 30.3% (>30d), respectively (P < 0.01). Composite adverse outcome occurred in 1669 (38.4%) CVs, and index AF episode >48 hours was an independent predictor for the composite endpoint (OR: 1.49, 95% CI: 1.28-1.74, P < 0.01) in multivariate analysis. CONCLUSIONS: Optimal timing of CV for AF showed a J-shaped curve, with fewest adverse outcomes in patients with CV performed 24 to 48 hours after onset of AF. In patients with rhythm-control strategy, delaying CV >48 hours is associated with increased risk for adverse outcomes.
Authors: D G Wyse; A L Waldo; J P DiMarco; M J Domanski; Y Rosenberg; E B Schron; J C Kellen; H L Greene; M C Mickel; J E Dalquist; S D Corley Journal: N Engl J Med Date: 2002-12-05 Impact factor: 91.245
Authors: Tapio Hellman; Tuomas Kiviniemi; Ilpo Nuotio; Tuija Vasankari; Juha Hartikainen; Gregory Y H Lip; K E Juhani Airaksinen Journal: Thromb Res Date: 2017-06-22 Impact factor: 3.944
Authors: Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas Journal: Eur Heart J Date: 2016-08-27 Impact factor: 29.983
Authors: Samuli Jaakkola; Gregory Y H Lip; Fausto Biancari; Ilpo Nuotio; Juha E K Hartikainen; Antti Ylitalo; K E Juhani Airaksinen Journal: Am J Cardiol Date: 2016-12-02 Impact factor: 2.778
Authors: Ron Pisters; Robby Nieuwlaat; Martin H Prins; Jean-Yves Le Heuzey; Aldo P Maggioni; A John Camm; Harry J G M Crijns Journal: Europace Date: 2012-01-05 Impact factor: 5.214
Authors: Rowlens M Melduni; Hon-Chi Lee; Kent R Bailey; Fletcher A Miller; David O Hodge; James B Seward; Bernard J Gersh; Naser M Ammash Journal: Am Heart J Date: 2015-07-30 Impact factor: 4.749
Authors: Tapio Hellman; Tuomas Kiviniemi; Tuija Vasankari; Ilpo Nuotio; Fausto Biancari; Aissa Bah; Juha Hartikainen; Marianne Mäkäräinen; K E Juhani Airaksinen Journal: BMC Cardiovasc Disord Date: 2017-01-18 Impact factor: 2.298
Authors: Tapio Hellman; Tuomas Kiviniemi; Ilpo Nuotio; Fausto Biancari; Tuija Vasankari; Juha Hartikainen; Mika Lehto; K E Airaksinen Journal: Clin Cardiol Date: 2018-07-23 Impact factor: 2.882
Authors: Nguyen Khac Le Son; Je Wook Park; Min Kim; Song Yi Yang; Hee Tae Yu; Tae Hoon Kim; Jae Sun Uhm; Boyoung Joung; Moon Hyoung Lee; Hui Nam Pak Journal: Korean Circ J Date: 2020-03-12 Impact factor: 3.243